---
title: "Too Tech for Clinical, Too Clinical for Tech"
excerpt_separator: "<!--more-->"
categories:
  - Modernization in Pharma & Clinical Data
tags:
  - industry-perspectives
  - modernization
  - industry-culture
  - systems-thinking

---

<div class="notice--info">
  This article examines the challenges of working at the intersection of highly regulated clinical research and fast-moving modern technology. It explores why innovation often stalls, the realities of vendor lock-in, and why a small group of ‚Äúbridge builders‚Äù is essential for meaningful progress.
</div>



---

<img src="/assets/images/vennDiagram.png" alt="vennDiagram" class="center-image" />

<p align="center">Image created by the author</p>

I work in a strange gray area; on one side: the highly regulated, cautiously paced world of clinical research ‚Äî pharmaceuticals, medical devices, health organizations ‚Äî where systems like Electronic Data Capture (EDC) keep trials running and regulators happy;

on the other side: modern tech engineering ‚Äî cloud platforms, automation, DevOps, platform engineering ‚Äî where the expectation is rapid iteration, frequent deployment, and ‚Äúif it‚Äôs not automated by next week, what are we even doing?‚Äù

Somehow, I‚Äôm *too tech for clinical* and *too clinical for tech*. And it‚Äôs‚Ä¶ a little like being bilingual in two dialects that don‚Äôt think they need translators.

---

## The Clinical Side: ‚ÄúWe Could Innovate‚Ä¶ But Why Rush?‚Äù
The clinical research world isn‚Äôt opposed to innovation ‚Äî it‚Äôs just heavily optimized for stability and compliance. Change is slow because:  
- Every new system must be validated.  
- Every process must meet regulatory expectations.  
- The stakes aren‚Äôt just uptime and user retention; they‚Äôre patient safety and data integrity.  

These are valid reasons. But they also mean that a lot of innovation falls into the ‚Äúmaybe someday‚Äù pile. If your system still works and still passes audits, the incentive to replace it is often very low.

---

## The Tech Side: ‚ÄúWe Can Totally Rebuild This By Friday‚Äù
Modern engineers can design platforms in days that would take years to approve in clinical research. They see slow-moving processes and think, *‚ÄúThis just needs better tooling.‚Äù*

Except‚Ä¶ it‚Äôs not just tooling. It‚Äôs also regulation, legacy interoperability, domain-specific standards, and workflows designed to satisfy auditors and sponsors ‚Äî not just end users.

When a tech team looks at clinical systems, they often underestimate:  
- The constraints that are non-negotiable.  
- The rules that can‚Äôt be ‚Äúoptimized away.‚Äù  
- The hidden complexity that‚Äôs invisible until you try to change it.  

---

## Why the Gray Area Matters
Working in this gray area means understanding two very different sets of priorities and being able to explain them to each other without either side glazing over.

It‚Äôs about:  
- Translating *‚Äúthis is how it‚Äôs always been done‚Äù* into *‚Äúhere‚Äôs how it could work better ‚Äî without breaking the rules.‚Äù*  
- Showing fast-moving engineers that not all obstacles are ‚Äútechnical debt‚Äù ‚Äî some are guardrails that exist for a reason.  
- Finding solutions that feel like progress to both sides, even if they define progress differently.  

> *The bridge doesn‚Äôt just connect two sides ‚Äî it‚Äôs what keeps progress alive.* ‚àû  

The bridge is the only thing that keeps them moving forward.

---

## The Part No One Talks About

<img src="/assets/images/void.png" alt="void" class="center-image" />

<p align="center">Image created by the author</p>

Here's the point: being in the middle feels like speaking into the void.  

The clinical side has the power to change but not the will ‚Äî their incentives are tied to compliance, not transformation. The engineering side has the skills to change things but not the desire, since the complexity is too messy, the regulations too restrictive, and the work is too far removed from what they know.  

That leaves a very small group of people ‚Äî people like me ‚Äî who *both* understand the potential and care enough to try.  

It‚Äôs a strange kind of isolation. You can see the path forward, but most of the audience you‚Äôre trying to reach is either uninterested, overwhelmed, or incentivized to keep things exactly as they are.  

> *If you don‚Äôt try to bridge the gap, nothing changes at all.*

---

## Why We Keep Choosing Pain Over Progress
Here‚Äôs the truth: many of the problems we face in clinical research already have elegant, battle-tested solutions in the wider tech world. Data ingestion, workflow automation, secure audit trails ‚Äî these are not unsolved problems. Modern engineering has been tackling them for years, if not decades, often with open-source or cloud-native tools that are more secure, scalable, and maintainable than what we‚Äôre using now.  

So why don‚Äôt we use them?  

Partly because the vendor ecosystem around pharma and regulated healthcare is built for one primary goal: meeting regulatory requirements. That‚Äôs important ‚Äî critical, even ‚Äî but it‚Äôs not the same as building with modern engineering or security best practices in mind. The result is software that passes audits but feels like it was designed in another decade‚Ä¶ because it was.  

These systems are often *painful* to use: clunky interfaces, rigid workflows, limited integration capabilities, and an overall sense that the user experience was an afterthought. And yet, they stay entrenched because:  
- They already ‚Äúwork‚Äù for compliance.  
- Switching is seen as high risk.  
- The culture rewards stability over experimentation.  

> *We pay huge sums for ‚Äúcustomizable‚Äù tools only to find that customization is priced so high it‚Äôs essentially off-limits.*  

And then there‚Äôs vendor lock-in ‚Äî the quiet trap that keeps the cycle going. I‚Äôve seen systems that violate the most basic IT principles ‚Äî like one software vendor's database system that defaulted every new user role to the *highest privilege level* and gave us no way to change it. That‚Äôs security 101: least privilege. The ‚Äúsolution?" Require every user to manually downgrade their own access **every** single time they logged in.  

This is a disaster waiting to happen from a security and data integrity perspective. It guarantees privilege creep, makes audit trails meaningless, and turns basic access control into a gamble on whether someone remembers an extra step.  

> *Does that sound like a solution to you?*  

So instead of getting the flexible, industry-specific tool we paid for, we‚Äôre left paying extra for workarounds just to make it usable at all.  

> *Are we paying for a solution, or for the privilege of staying stuck?*  

The irony is that the safest path forward may not be to reinvent from scratch, but to **adapt proven, modern systems** ‚Äî the ones already used successfully in other industries ‚Äî and apply them with the same rigor we use to validate any new clinical technology.  

Until we do that, we‚Äôre choosing the comfort of the familiar over the possibility of the better.  

> *That choice has a cost, even if it‚Äôs not measured in revenue or patient safety ‚Äî it‚Äôs measured in the day-to-day frustration of the people trying to actually get the work done.*

---

## The Real Challenge... And Opportunity
This gray area can be frustrating, but it‚Äôs also where the most meaningful change happens. Progress here isn‚Äôt about grand overhauls ‚Äî it‚Äôs about finding small, strategic incramental shifts that work for teams.

It‚Äôs where you can:  
- Spot opportunities to simplify without oversimplifying.  
- Introduce improvements in a way that feels safe to adopt.  
- Build trust so that when bigger changes are needed, both sides are ready for them.  

It‚Äôs not about moving fast ‚Äî it‚Äôs about moving smart, earning buy-in, and fixing the right things in a secure and compliant manner.

---

If you‚Äôre in this space too, you know the tension ‚Äî and the silence, but you also know that the people who can bridge these worlds are rare, and necessary.  

We may be few, but we‚Äôre the ones who show what‚Äôs possible.  

> *That‚Äôs what being too tech for clinical and too clinical for tech is all about.*

üí¨ If you're enjoying the ideas here and want to stay connected, feel free to [connect with me on LinkedIn](https://www.linkedin.com/in/mlogan914/). I‚Äôd love to stay in touch with others thinking about the future of clinical data and systems design.

---

> **Disclaimer:** This article reflects my personal views only and is for informational purposes. It does not represent professional advice or the positions of any past or current employer. No confidential or proprietary information is shared, and I disclaim all liability for how you use its content. Third-party links or tool mentions are not endorsements.